Dr. Jesús San Miguel Izquierdo is a hematologist associated with Clínica Universidad de Navarra and its Cancer Center in Spain. He specializes in hematology and hemotherapy, with a particular focus on multiple myeloma, plasma cell disorders, and the development of new treatments for hematologic malignancies.

According to his official clinical profile, he graduated in Medicine from the University of Navarra in 1976 and completed his hematology specialization in 1980. His professional career includes clinical care, university teaching, and extensive research into blood cancers.

Specialization in Multiple Myeloma

Multiple myeloma is a cancer involving plasma cells, a type of white blood cell responsible for producing antibodies. The disease can affect bone marrow, bones, kidney function, and blood cell production.

Diagnosis generally involves blood and urine testing, bone marrow examination, imaging, and other investigations based on the patient's clinical condition. These assessments help determine disease activity, complications, and treatment requirements.

Dr. San Miguel's documented areas of interest include multiple myeloma and minimal residual disease. Minimal residual disease testing can detect very small amounts of cancer cells after treatment and may help clinicians evaluate treatment response.

Hematologic Oncology and Blood Disorders

Hematology covers the diagnosis and management of disorders affecting blood cells, bone marrow, and the lymphatic system. Hematologic cancers include multiple myeloma, leukemia, lymphoma, and related malignancies.

Treatment depends on the precise diagnosis, disease stage, molecular and genetic findings, previous treatment, and general health of the patient.

Depending on the condition, management may involve chemotherapy, targeted medicines, immunotherapy, antibody-based treatments, stem cell transplantation, or supportive care. Not every option is suitable for every patient.

Research and Development of New Treatments

Dr. San Miguel's official biography records participation in more than 50 national research projects, five European projects, and two American projects. He has also served as principal investigator in more than 35 clinical trials.

His research interests include the development of new antitumor medicines and methods for assessing treatment response. He has contributed extensively to international scientific publications and hematology education.

This research background is relevant to patients seeking specialist evaluation of complex blood cancers or information about emerging treatment approaches. Clinical trial eligibility depends on the individual diagnosis, protocol requirements, and current availability.

Academic and Professional Contributions

Dr. San Miguel has served as a professor of hematology at the University of Navarra. His academic work includes medical education, scientific presentations, research supervision, and contributions to medical literature.

His documented awards include the Gregorio Marañón National Award in Medicine in 2021 and the Jan Gosta Waldenström Award in 2022.

International Patient Information

International patients considering hematology consultation in Spain should prepare recent blood counts, bone marrow biopsy reports, pathology results, cytogenetic and molecular testing, imaging studies, and a summary of previous treatments.

These records help the specialist assess the diagnosis and determine whether additional testing or treatment review is required.

Treatment recommendations, transplantation suitability, and clinical trial eligibility require individualized medical assessment.